Wuhan Healthgen Biotechnology (SHSE:688765) Net Margin %: -374.39% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688765 Wuhan Healthgen Biotechnology Corp SHSE:688765
19 GF Score
Price ¥54.61
! 7 Warning Signs
View Full Analysis

What is Wuhan Healthgen Biotechnology Net Margin %?

Wuhan Healthgen Biotechnology SHSE:688765 +4.66% 19 Net Margin % is -374.39% as of Mar. 2026. GuruFocus rates SHSE:688765 with a GF Score™ of 19/100. The stock has 7 warning signs investors should review. Among 962 Drug Manufacturers companies, Wuhan Healthgen Biotechnology ranks worse than 94.18% on this metric.

Net margin is calculated as Net Income divided by its Revenue. Wuhan Healthgen Biotechnology's Net Income for the three months ended in Mar. 2026 was ¥-36.05 Mil. Wuhan Healthgen Biotechnology's Revenue for the three months ended in Mar. 2026 was ¥9.63 Mil. Therefore, Wuhan Healthgen Biotechnology's net margin for the quarter that ended in Mar. 2026 was -374.39%.

The historical rank and industry rank for Wuhan Healthgen Biotechnology's Net Margin % or its related term are showing as below:

SHSE:688765' s Net Margin % Range Over the Past 10 Years
Min: -1071.46   Med: -562.78   Max: -247.39
Current: -271.6

SHSE:688765's Net Margin % is ranked worse than
94.18% of 962 companies
in the Drug Manufacturers industry
Industry Median: 5.56 vs SHSE:688765: -271.60

Wuhan Healthgen Biotechnology  (SHSE:688765) Net Margin % Explanation

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.

Wuhan Healthgen Biotechnology Net Margin % Related Terms

Wuhan Healthgen Biotechnology Net Margin % Historical Data

* Premium members only.

The historical data trend for Wuhan Healthgen Biotechnology's Net Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Wuhan Healthgen Biotechnology Net Margin % Chart

Wuhan Healthgen Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Net Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -525.26 -1,071.46 -770.54 -600.29 -328.11

Wuhan Healthgen Biotechnology Quarterly Data
Dec15 Jun16 Dec16 Jun17 Dec17 Dec19 Dec20 Dec21 Jun22 Dec22 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Net Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1,163.29 -390.25 -570.40 -126.83 -374.39

SHSE:688765 vs ZTS, UTHR: Net Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Wuhan Healthgen Biotechnology's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Wuhan Healthgen Biotechnology Net Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Wuhan Healthgen Biotechnology's Net Margin % distribution charts can be found below:

* The bar in red indicates where Wuhan Healthgen Biotechnology's Net Margin % falls into.


SHSE:688765
19GF Score
Wuhan Healthgen Biotechnology Corp SHSE:688765
Net Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Wuhan Healthgen Biotechnology Net Margin % Calculation

Net margin - also known as net profit margin is the ratio of Net Income divided by net sales or Revenue, usually presented in percent.

Wuhan Healthgen Biotechnology's Net Margin for the fiscal year that ended in Dec. 2025 is calculated as

Net Margin=Net Income (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-157.037/47.861
=-328.11 %

Wuhan Healthgen Biotechnology's Net Margin for the quarter that ended in Mar. 2026 is calculated as

Net Margin=Net Income (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-36.046/9.628
=-374.39 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Net Margin % →
What does a Net Margin % of -374.39% mean?
Wuhan Healthgen Biotechnology (SHSE:688765) has a Net Margin % of -374.39% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Wuhan Healthgen Biotechnology and its competitors. According to the industry distribution chart, Wuhan Healthgen Biotechnology ranks #906 out of 962 companies in the Drug Manufacturers industry, placing it in the top 94.2%.
Is Wuhan Healthgen Biotechnology's Net Margin % too high?
Wuhan Healthgen Biotechnology's current Net Margin % is -374.39%. Based on the distribution chart, Wuhan Healthgen Biotechnology ranks #906 out of 962 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Wuhan Healthgen Biotechnology has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Wuhan Healthgen Biotechnology's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wuhan Healthgen Biotechnology ranks #906 out of 962 companies for Net Margin %. This places Wuhan Healthgen Biotechnology in the lower half of its industry. The industry median Net Margin % is 5.56. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 962 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Wuhan Healthgen Biotechnology and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wuhan Healthgen Biotechnology's current Net Margin % is -374.39%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wuhan Healthgen Biotechnology stock overvalued right now?
Wuhan Healthgen Biotechnology (SHSE:688765) has a current Net Margin % of -374.39%. The current Net Margin % is -374.39%. Wuhan Healthgen Biotechnology's overall GF Score™ is 19/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Wuhan Healthgen Biotechnology (SHSE:688765), the current Net Margin % is -374.39% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Wuhan Healthgen Biotechnology Business Description

Address No. 268, Shendun 5th Road, East Lake New Technology Development Zone, Hubei Province, Wuhan, CHN, 430206
Wuhan Healthgen Biotechnology Corp is engaged in Research, development, production and commercialization of plant-based molecular medicines.
19GF Score

Get the complete analysis for SHSE:688765

Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥54.61
Price